We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Diatron MI Plc

Develops, manufactures and markets hematology analyzers, clinical chemistry analyzers, and associated reagents for hu... read more Featured Products: More products

Download Mobile App





Diatron Introduces New Aquila 5Dretic 5-Part Differential Hematology Analyzer

By LabMedica International staff writers
Posted on 20 Nov 2019
Diatron (Budapest, Hungary) introduced its new high throughput, 5-part differential hematology analyzer with continuous loading autoloader for the first time at the MEDICA 2019 Trade Fair held in Düsseldorf, Germany from 18-21st November. More...
The MEDICA is the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals.

Diatron, a global provider of hematology and clinical chemistry analyzers, also showcased its P500 flagship clinical chemistry analyzer, and the Diatron KleeYa, an open, flexible CLIA platform, and demonstrated the Aquila 3-part diff hematology analyzer from its current hematology product portfolio.

The Diatron Aquila 5Dretics is the smallest and most compact cap piercing 5-part differential hematology analyzer with a maximum throughput of 80 tests per hour. It has a low reagent consumption (<30 ml), requires a small sample volume (40 ul) and has a continuous loading autoloader, making the walk away system convenient for all customers. It uses only two reagents as it is a fully optical system, resulting in low reagent consumption and making it more cost-effective. The Diatron Aquila 5Dretics requires little bench space (32 cm W x 30 cm D x 37 cm H without autoloader) and features a large touch screen, an intuitive user interface and a protected reagent pack system with unique connection

At the 2019 edition of MEDICA, Diatron also showcased its P500 flagship clinical chemistry analyzer. The P500 is an ergonomically designed, user-friendly system that offers a high level of automation and delivers assured result quality. The cost-effective, walkaway system is intended for medium throughput usage, providing results for 215 tests per hour on a typical sample mix. Also showcased at the event was Diatron KleeYa, a highly flexible, fast and sensitive random access chemiluminescence platform that provides a unique approach to the use of different bead-based chemiluminescence technologies, offering superior assay performance and providing ease of use with cost containment. The open platform system features a unique trigger cartridge technology that allows the use of both flash and glow detection technologies, along with unique stackable reaction cuvettes to eliminate system handling errors and reduce shipping and storage space.

Additionally, Diatron demonstrated the Aquila 3-part diff hematology analyzer which offers a throughput of 60 tests per hour, requires a sample size of only 10µl, and consumes less than 10ml of reagent per test. It is equipped with an onboard reagent pack sufficient for approximately 200 measurements and includes a touchscreen, intuitive user interface, optional backup battery pack, and extended connectivity options.

Related Links:
Diatron


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Pipette Calibration System
Artel PCS®
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Single Genetic Analysis Identifies Causes of Premature Ovarian Insufficiency

Premature ovarian insufficiency (POI) affects up to 3.5% of women and represents a major cause of infertility. In most cases, the underlying etiology remains unknown, making patient counseling and clinical... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.